NFX 88
Treatment for pain
caused by spinal cord injuries
NFX 88 – Neuropathic Pain (NP)
Our product, NFX88, is a first-class drug formulated to relieve neuropathic pain experienced by many patients who have suffered some type of spinal cord injury (SCI). Spinal cord injuries generally arise as a result of trauma, disease, or degeneration, leading to a wide range of health complications depending on the severity and location of the injury in the spinal cord.
One such complication is neuropathic pain, a type of chronic pain that is initiated or caused by a primary lesion or dysfunction of the nervous system In patients with spinal cord injuries, neuropathic pain appears in the months following the injury, progresses for about 3-5 years before reaching a plateau, and may persist for many years after the acute injury. Neuropathic pain has a substantial negative impact on the function and quality of life of the patient, and 17% of patients have health-related quality of life scores equivalent to “worse than death”.
The current treatment options are inadequate, relying on combinations of drugs that result in numerous side effects, and typically only lead to a 20-30% reduction in pain intensity for a limited group of patients.
Our product, NFX88, with a unique lipid-based structure (2-hydroxyoleic acid), is specifically designed to relieve neuropathic pain. It stands out from conventional medications by directly targeting cell membranes. It possesses a unique mechanism of action that involves interaction with these membranes, altering their molecular composition and physicochemical properties.
As a result, a series of internal changes occur in the cell, leading to a decrease in the production of proinflammatory substances (e.g., lysophosphatidic acid or phospholipase A) and an increase in molecules related to neuronal growth and repair mechanisms (e.g., GDF10, TNC).
The subsequent changes carried out by these regulatory molecules result in the reduction of histopathological and structural processes that had initiated the pain, ultimately leading to the decrease of neuropathic pain itself.
NFX 88 – CLINICAL TRIALS
NFX88 has already demonstrated its tolerance in patients during the Phase I of the clinical trial (NCT01792310) and its high safety and therapeutic efficacy profile in Phase IIA (2018-004792-13). The most promising results are related to the high number of patients experiencing pain relief after treatment with NFX88 without suffering from related adverse effects.
After successfully concluding Phase IIA, the Neurofix Pharma team is preparing the protocol for the next phase of the clinical trial (Phase IIB/III), scheduled to commence later this year. This phase of the trial will be conducted in approximately 30 hospitals across different countries in the European Union and will be the final step before the product’s commercialization, assuming the expected results are achieved.
LEAD INVESTIGATORS
Dr. Antonio Oliviero
National Hospital for Paraplegics.
(Toledo)
Dr. Sebastián Salvador
University Hospital
(A Coruña)
Dra. Judith Sánchez
University Vall d’Hebron Hospital
(Barcelona)
Dr. Miguel D. Membrilla
University Vall d’Hebron Hospital
Dr. Joan Vidal
Guttmann Institute
(Barcelona)
Dra. Natacha León
Los Madroños Hospital
(Brunete – Madrid)
Dra. Juana Mª Barrera
Universitary Virgen del Rocio (Sevilla) Hospital
Dr. Antonio Oliviero
National Hospital for Paraplegics.
(Toledo)
Main Publications
Below you will find a section dedicated to the collection of publications that reflect Antonio Oliviero’s extensive knowledge in the field of neuropathic pain.
Our renowned expert in the field of neuropathic pain has invested years of research and clinical experience to understand the intricate complexity of this pain.
From detailed descriptions of the neurobiological basis to innovative approaches to treatment and management, these publications offer profound and enriching information about the impact of neuropathic pain on patients and the medical community at large.
Some of his most significant works include:
- Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS), Clinical Neurophysiology, Volume 125, Issue 11, 2014, Pages 2150 2206, ISSN 1388-2457, https://doi.org/10.1016/j.clinph.2014.05.021.
- A practical guide to diagnostic transcranial magnetic stimulation: Report of an IFCN committee, Clinical Neurophysiology, Volume 123, Issue 5, 2012, Pages 858-882, ISSN 1388-2457, https://doi.org/10.1016/j.clinph.2012.01.010.
- Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018), Clinical Neurophysiology, Volume 131, Issue 2, 2020, Pages 474-528, ISSN 1388-2457, https://doi.org/10.1016/j.clinph.2019.11.002.
ACTUALIDAD NEUROFIX
Neurofix Pharma will participate in the major biotechnology events.24 de August de 2023 - 13:33
Neurofix Pharma presents the successful results of its phase IIA clinical trial to institutions and businessmen in Salamanca28 de November de 2022 - 08:46
Mañueco visits the offices of Neurofix Pharma, the first biotech company in Castilla y León to successfully complete phase IIA of a clinical trial11 de November de 2022 - 15:42